Common Secondary Causes of Resistant Hypertension and Rational for Treatment
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Resistant hypertension is defined as uncontrolled blood pressure despite the use of three antihypertensive drugs, including a diuretic, in optimal doses. Treatment resistance can be attributed to poor adherence to antihypertensive drugs, excessive salt intake, physician inertia, inappropriate or inadequate medication, and secondary hypertension. Drug-induced hypertension, obstructive sleep apnoea, primary aldosteronism, and chronic kidney disease represent the most common secondary causes of resistant hypertension. Several drugs can induce or exacerbate pre-existing hypertension, with non-steroidal anti-inflammatory drugs being the most common due to their wide use. Obstructive sleep apnoea and primary aldosteronism are frequently encountered in patients with resistant hypertension and require expert management. Hypertension is commonly found in patients with chronic kidney disease and is frequently resistant to treatment, while the management of renovascular hypertension remains controversial. A step-by-step approach of patients with resistant hypertension is proposed at the end of this review paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension
Peppard, P. E., Young, T., Palta, M., & Skatrud, J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005113421901 · Cited by 4,973 · cited 1×
“from specialized clinics [80–83].”
Marin, J. M., Carrizo, S. J., Vicente, E., & Agusti, A. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71141-7 · Cited by 4,678
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Circulation · doi:10.1161/01.cir.0000154900.76284.f6 · Cited by 3,985
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Nieto, F. J. (2000) · JAMA · doi:10.1001/jama.283.14.1829 · Cited by 3,369
Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.12.013 · Cited by 2,796 · cited 1×
“It has to be noted that although acetaminophen is considered to have a better safety profile than NSAIDs [16, 17], its use was associated with a moderate increase in the risk for incident hypertension in both males and females [18, 19].”
BackgroundDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Adherence to Continuous Positive Airway Pressure Therapy: The Challenge to Effective Treatment
Weaver, T. E., & Grunstein, R. R. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200708-119mg · Cited by 1,680 · cited 1×
“Moreover, among CPAP users, 29–83% used it for less than 4 hours [118].”
BackgroundA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 1×
“performed in the last decade report amuch higher prevalence of PA (>10%), suggesting an “epidemic” of this condition [128–133].”
BackgroundPhillips, L. S., Branch, W. T., Cook, C. B., Doyle, J. P., El-Kebbi, I. M., Gallina, D. L., Miller, C. D., Ziemer, D. C., & Barnes, C. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-9-200111060-00012 · Cited by 1,370
Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., Dinçer, F., Dziedzic, K., Häuselmann, H. J., Herrero-Beaumont, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062091 · Cited by 1,338 · cited 1×
“It has to be noted that although acetaminophen is considered to have a better safety profile than NSAIDs [16, 17], its use was associated with a moderate increase in the risk for incident hypertension in both males and females [18, 19].”
BackgroundCushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Self-citationMulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
High prevalence of unrecognized sleep apnoea in drug-resistant hypertension
Logan, A. G., Perlikowski, S. M., Mente, A., Tisler, A., Tkacova, R., Niroumand, M., Leung, R. S. T., & Bradley, T. D. (2001) · Journal of Hypertension · doi:10.1097/00004872-200112000-00022 · Cited by 960 · cited 1×
“In a study of 41 consecutive resistant hypertensives, an 83% prevalence of unsuspected OSA was found; OSA was defined as an apnea/hypopnea index (AHI) of more than 10 events per hour [85].”
BackgroundBecker, H. F., Jerrentrup, A., Ploch, T., Grote, L., Penzel, T., Sullivan, C. E., & Peter, J. H. (2003) · Circulation · doi:10.1161/01.cir.0000042706.47107.7a · Cited by 931
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B., & Weissmann, P. (2002) · Hypertension · doi:10.1161/01.hyp.0000040261.30455.b6 · Cited by 763
Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis
Johnson, A. G., Nguyen, T. V., & Day, R. O. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00011 · Cited by 717
FACCENDA, J. F., MACKAY, T. W., BOON, N. A., & DOUGLAS, N. J. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.2.2005037 · Cited by 631 · cited 1×
“However, the long-term effects of CPAP on blood pressure are controversial, from studies reporting a significant decrease in blood pressure to studies reporting small or no effects [92–106].”
BackgroundBazzano, L. A., Khan, Z., Reynolds, K., & He, J. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.085175 · Cited by 543
Barbé, F., Mayoralas, L. R., Duran, J., Masa, J. F., Maimó, A., Montserrat, J. M., Monasterio, C., Bosch, M., Ladaria, A., Rubio, M., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-11-200106050-00007 · Cited by 534 · cited 1×
“However, the long-term effects of CPAP on blood pressure are controversial, from studies reporting a significant decrease in blood pressure to studies reporting small or no effects [92–106].”
BackgroundPimenta, E., Gaddam, K. K., Oparil, S., Aban, I., Husain, S., Dell'Italia, L. J., & Calhoun, D. A. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131235 · Cited by 531
A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure
Pope, J. E. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410040045007 · Cited by 527
Doherty, L. S., Kiely, J. L., Swan, V., & McNicholas, W. T. (2005) · Chest · doi:10.1378/chest.127.6.2076 · Cited by 485 · cited 1×
“It has been shown that CPAP decreases the incidence of cardiovascular events in patients with OSA [89, 90].”
BackgroundFardella, C. E., Mosso, L., Gómez-Sánchez, C., Cortés, P., Soto, J., Gómez, L., Pinto, M., Huete, A., Oestreicher, E., Foradori, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6596 · Cited by 463
Long-term Effect of Continuous Positive Airway Pressure in Hypertensive Patients with Sleep Apnea
Barbé, F., Durán-Cantolla, J., Capote, F., de la Peña, M., Chiner, E., Masa, J. F., Gonzalez, M., Marín, J. M., Garcia-Rio, F., de Atauri, J. D., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0050oc · Cited by 460
PIERDOMENICO, S., LAPENNA, D., BUCCI, A., DITOMMASO, R., DIMASCIO, R., MANENTE, B., CALDARELLA, M., NERI, M., CUCCURULLO, F., & MEZZETTI, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.05.014 · Cited by 409 · cited 1×
“It has been noted that in 20–30% of patients with resistant hypertension, treatment resistance may be attributed to the “white coat” effect [143, 190–192].”
BackgroundAnderson, G. H., Blakeman, N., & Streeten, D. H. P. (1994) · Journal of Hypertension · doi:10.1097/00004872-199405000-00015 · Cited by 403
Alonso, A., Lau, J., Jaber, B. L., Weintraub, A., & Sarnak, M. J. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.09.009 · Cited by 345
Pratt-Ubunama, M. N., Nishizaka, M. K., Boedefeld, R. L., Cofield, S. S., Harding, S. M., & Calhoun, D. A. (2007) · Chest · doi:10.1378/chest.06-1442 · Cited by 331
A Randomized Controlled Trial of Continuous Positive Airway Pressure in Mild Obstructive Sleep Apnea
Barnes, M., Houston, D., Worsnop, C. J., Neill, A. M., Mykytyn, I. J., Kay, A., Trinder, J., Saunders, N. A., McEvoy, R. D., & Pierce, R. J. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2003166 · Cited by 329 · cited 1×
“However, the long-term effects of CPAP on blood pressure are controversial, from studies reporting a significant decrease in blood pressure to studies reporting small or no effects [92–106].”
BackgroundMeta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329 · cited 1×
“34mmHg) [30].”
Prospective Study of Oral Contraceptives and Hypertension Among Women in the United States
Chasan-Taber, L., Willett, W. C., Manson, J. E., Spiegelman, D., Hunter, D. J., Curhan, G., Colditz, G. A., & Stampfer, M. J. (1996) · Circulation · doi:10.1161/01.cir.94.3.483 · Cited by 328 · cited 1×
“The larger study evaluating the effects of oral contraceptives on blood pressure was the Nurses’ Health Study, in which more than 60,000 normotensive women were prospectively followed for 4 years [50].”
BackgroundRobinson, G. V., Smith, D. M., Langford, B. A., Davies, R. J. O., & Stradling, J. R. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00062805 · Cited by 314
Gallay, B. J., Ahmad, S., Xu, L., Toivola, B., & Davidson, R. C. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80117-7 · Cited by 304
Gaddam, K., Pimenta, E., Thomas, S. J., Cofield, S. S., Oparil, S., Harding, S. M., & Calhoun, D. A. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2009.96 · Cited by 289 · cited 1×
“Even more interestingly, however, spironolactone was shown not only to significantly lower blood pressure in 12 patients with OSA and resistant hypertension, but to reduce the severity of OSA as well [120].”
Background(2006) · Obstetrics & Gynecology · doi:10.1097/00006250-200606000-00055 · Cited by 277
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment
Eide, I. K., Torjesen, P. A., Drolsum, A., Babovic, A., & Lilledahl, N. P. (2004) · Journal of Hypertension · doi:10.1097/00004872-200411000-00026 · Cited by 265 · cited 1×
“similar in two other studies, one from Seattle (17%) and one from Norway (23%) [139, 140].”
ResultŠtrauch, B., Zelinka, T., Hampf, M., Bernhardt, R., & Widimsky, J. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001554 · Cited by 237
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
de Souza, F., Muxfeldt, E., Fiszman, R., & Salles, G. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140988 · Cited by 234
Pépin, J.-L., Tamisier, R., Barone-Rochette, G., Launois, S. H., Lévy, P., & Baguet, J.-P. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1803oc · Cited by 232 · cited 1×
“It is, therefore, not surprising that in a recent randomized study, valsartan was more effective than CPAP in hypertensive patients with OSA [110].”
ResultSchwartz, G. L., & Turner, S. T. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041780 · Cited by 221
Initiation of Antihypertensive Treatment During Nonsteroidal Anti-inflammatory Drug Therapy
Gurwitz, J. H. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520100043031 · Cited by 220 · cited 1×
“Another large, case-control study revealed a 66% increased risk for initiating antihypertensive drugs in NSAIDs users compared to nonusers [20].”
BackgroundVascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy
Shinkaruk, S., Bayle, M., Lain, G., & Deleris, G. (2003) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011033353452 · Cited by 219 · cited 1×
“A monoclonal antibody (bevacizumab) binding to the VEGF-A isoform, as well as small molecules inhibiting the intracellular tyrosine kinase domains of all three VEGF receptors, is used or is under clinical testing for the treatment of various malignancies [55–57].”
MethodCPAP and measures of cardiovascular risk in males with OSAS
Kohler, M., Pepperell, J. C. T., Casadei, B., Craig, S., Crosthwaite, N., Stradling, J. R., & Davies, R. J. O. (2008) · European Respiratory Journal · doi:10.1183/09031936.00026608 · Cited by 197 · cited 1×
“However, the long-term effects of CPAP on blood pressure are controversial, from studies reporting a significant decrease in blood pressure to studies reporting small or no effects [92–106].”
BackgroundNon-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women
Forman, J. P., Stampfer, M. J., & Curhan, G. C. (2005) · Hypertension · doi:10.1161/01.hyp.0000177437.07240.70 · Cited by 196
Gonzaga, C. C., Gaddam, K. K., Ahmed, M. I., Pimenta, E., Thomas, S. J., Harding, S. M., Oparil, S., Cofield, S. S., & Calhoun, D. A. (2010) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27878 · Cited by 188 · cited 1×
“In one study of 109 patients with resistant hypertension, OSA was found in 84% of patients with PA [144].”
BackgroundNonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Dedier, J., Stampfer, M. J., Hankinson, S. E., Willett, W. C., Speizer, F. E., & Curhan, G. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000035856.77718.da · Cited by 145 · cited 1×
“Two large prospective cohort studies in normotensive women reported higher risks of subsequent hypertension among NSAIDs users than in women without regular NSAIDs administration [14, 15].”
BackgroundRADACK, K. L., DECK, C. C., & BLOOMFIELD, S. S. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-628 · Cited by 140 · cited 1×
“findings were observed in two small randomized studies regarding the effects of acetaminophen on blood pressure [25, 26], as well as in studies evaluating the effects of aspirin on blood pressure in hypertensive patients [27, 28].”
BackgroundAngiogenesis Inhibitors and Hypertension: An Emerging Issue
Sica, D. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5740 · Cited by 127 · cited 2×
“The recognition of the pathogenetic mechanisms that contribute to blood pressure elevation with VEGF-inhibitors might be helpful in identifying the most appropriate drugs for the management of these patients.”
BackgroundDi Murro, A., Petramala, L., Cotesta, D., Zinnamosca, L., Crescenzi, E., Marinelli, C., Saponara, M., & Letizia, C. (2010) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310366581 · Cited by 125
White, W. B., Hanes, V., Chauhan, V., & Pitt, B. (2006) · Hypertension · doi:10.1161/01.hyp.0000232179.60442.84 · Cited by 119 · cited 1×
“On the contrary, drospirenone (a fourth generation progestin) reduces blood pressure when combined with estradiol [52].”
BackgroundMorgan, T. O., Anderson, A., & Bertram, D. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01204-8 · Cited by 102 · cited 6×
“Another study among hypertensive patients with osteoarthritis, comparing the effects of rofecoxib and celecoxib, revealed no differences on blood pressure between the two drugs in patients taking diuretics or calcium antagonists, whereas larger blood pressure elevations were observed with rofecoxib than with celecoxib…”
BackgroundInfluentialDernaika, T. A., Kinasewitz, G. T., & Tawk, M. M. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27435 · Cited by 102
MARTELL, N., RODRIGUEZ-CERRILLO, M., GROBBEE, D. E., LÓPEZ-EADY, M. D., FERNÁNDEZ-PINILLA, C., AVILA, M., FERNANDEZ-CRUZ, A., & LUQUE, M. (2003) · Blood Pressure · doi:10.1080/08037050310009950 · Cited by 49 · cited 1×
“A study from Spain reported a 14% prevalence of primary hyperaldosteronism in patients with refractory hypertension; however, patients with hypokalemia were excluded from the study suggesting that the true prevalence of primary aldosteronism could be up to two times higher than the one reported [141].”
BackgroundGrøn sælen, M., Katrine prøsch, L., Gudmundsdottir, H., Dyrbekk, D., Helge Hunderi, O., Arnesen, E., Paulsen, D., Skjønsberg, H., & Os, I. (2005) · Blood Pressure · doi:10.1080/08037050510008959 · Cited by 17 · cited 1×
“It has been shown, however, that the vast majority (>85%) of patients with CKD fail to achieve these goals; blood pressure control rates in CKD patients are lower than in other hypertensive patients despite the use of 3 antihypertensive drugs in average [152, 153].”
Background
Cited by
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Gut–Brain Axis in Regulation of Blood Pressure
Yang, T., & Zubcevic, J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00845 · Cited by 74
“, 2013); obesity (Lohmeier and Iliescu, 2013); prescription drugs (Faselis et al., 2011); heavy alcohol consumption (Pimenta et al.”
BackgroundDiagnosis and management of resistant hypertension: state of the art
Wei, F.-F., Zhang, Z.-Y., Huang, Q.-F., & Staessen, J. A. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0006-6 · Cited by 39
Primary aldosteronism in patients with adrenal incidentaloma: is screening appropriate for everyone?
Stavropoulos, K., Imprialos, K. P., Katsiki, N., Petidis, K., Kamparoudis, A., Petras, P., Georgopoulou, V., Finitsis, S., Papadopoulos, C., Athyros, V. G., et al. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13291 · Cited by 23
Self-citation
Metadata
- Authors
- Faselis, C., Doumas, M., & Papademetriou, V.
- Venue
- International Journal of Hypertension
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-17
- ISSN
- 2090-0384 (ISSN-L)
- 2090-0392
- OpenAlex
- W1965128357
- Cited by
- 85
- References
- 57
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.